Ontology highlight
ABSTRACT:
INSTRUMENT(S): Illumina HiSeq 4000
ORGANISM(S): Homo sapiens
SUBMITTER: Jerome Tamburini
PROVIDER: E-MTAB-10048 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
Decroocq Justine J Birsen Rudy R Montersino Camille C Chaskar Prasad P Mano Jordi J Poulain Laury L Friedrich Chloe C Alary Anne-Sophie AS Guermouche Helene H Sahal Ambrine A Fouquet Guillemette G Gotanègre Mathilde M Simonetta Federico F Mouche Sarah S Gestraud Pierre P Lescure Auriane A Del Nery Elaine E Bosc Claudie C Grenier Adrien A Mazed Fetta F Mondesir Johanna J Chapuis Nicolas N Ho Liza L Boughalem Aicha A Lelorc'h Marc M Gobeaux Camille C Fontenay Michaela M Recher Christian C Vey Norbert N Guillé Arnaud A Birnbaum Daniel D Hermine Olivier O Radford-Weiss Isabelle I Tsantoulis Petros P Collette Yves Y Castellano Rémy R Sarry Jean-Emmanuel JE Pasmant Eric E Bouscary Didier D Kosmider Olivier O Tamburini Jerome J
Leukemia 20220330 5
Despite recent advances in acute myeloid leukemia (AML) molecular characterization and targeted therapies, a majority of AML cases still lack therapeutically actionable targets. In 127 AML cases with unmet therapeutic needs, as defined by the exclusion of ELN favorable cases and of FLT3-ITD mutations, we identified 51 (40%) cases with alterations in RAS pathway genes (RAS+, mostly NF1, NRAS, KRAS, and PTPN11 genes). In 79 homogeneously treated AML patients from this cohort, RAS+ status were asso ...[more]